OBJECTIVES: To estimate the in vivo fitness cost of enfuvirtide (ENF) resistance, we analyzed dynamic shifts in the HIV-1 quasispecies under changing selective pressure in 3 subjects on failing ENF-based regimens who interrupted ENF while maintaining stable background regimens. Subsequently, ENF was readministered for 4 weeks as "pulse intensification." METHODS: The proportion of plasma virus carrying the V38A mutation in gp41 was quantified by allele-specific real-time polymerase chain reaction in serial samples collected from 3 subjects at 1- to 4-week intervals. Fitness differences were calculated using a method that corrected for time dependence of the viral replication rate. RESULTS: The V38A mutant made up >or=85% of the quasispecies at baseline and decayed to <5% over 12-24 weeks; plasma HIV-1 RNA levels remained stable during this time. Fitness differences for mutant versus wild type ranged from -25% to -65%, providing in vivo evidence for the reduced fitness of ENF-resistant HIV-1. The V38A mutant virus reemerged rapidly during the ENF pulse. CONCLUSIONS: These results demonstrate that the HIV-1 quasispecies undergoes dynamic changes in response to withdrawal and reinitiation of fusion inhibitor therapy. The relative stability of plasma HIV-1 titers during decay of V38A suggests that factors other than viral fitness likely define viral load set-point in patients with advanced disease.
OBJECTIVES: To estimate the in vivo fitness cost of enfuvirtide (ENF) resistance, we analyzed dynamic shifts in the HIV-1 quasispecies under changing selective pressure in 3 subjects on failing ENF-based regimens who interrupted ENF while maintaining stable background regimens. Subsequently, ENF was readministered for 4 weeks as "pulse intensification." METHODS: The proportion of plasma virus carrying the V38A mutation in gp41 was quantified by allele-specific real-time polymerase chain reaction in serial samples collected from 3 subjects at 1- to 4-week intervals. Fitness differences were calculated using a method that corrected for time dependence of the viral replication rate. RESULTS: The V38A mutant made up >or=85% of the quasispecies at baseline and decayed to <5% over 12-24 weeks; plasma HIV-1 RNA levels remained stable during this time. Fitness differences for mutant versus wild type ranged from -25% to -65%, providing in vivo evidence for the reduced fitness of ENF-resistant HIV-1. The V38A mutant virus reemerged rapidly during the ENF pulse. CONCLUSIONS: These results demonstrate that the HIV-1 quasispecies undergoes dynamic changes in response to withdrawal and reinitiation of fusion inhibitor therapy. The relative stability of plasma HIV-1 titers during decay of V38A suggests that factors other than viral fitness likely define viral load set-point in patients with advanced disease.
Authors: Thomas E Melby; Michael Despirito; Ralph A Demasi; Gabrielle Heilek; James A Thommes; Michael L Greenberg; Neil Graham Journal: AIDS Date: 2007-11-30 Impact factor: 4.177
Authors: C A Derdeyn; J M Kilby; G D Miralles; L F Li; G Sfakianos; M S Saag; R D Hockett; R P Bucy Journal: J Infect Dis Date: 1999-12 Impact factor: 5.226
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo Journal: N Engl J Med Date: 2003-05-29 Impact factor: 91.245
Authors: Sebastian Bonhoeffer; Georg A Funk; Huldrych F Günthard; Marek Fischer; Viktor Müller Journal: Trends Microbiol Date: 2003-11 Impact factor: 17.079
Authors: Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2012-05-21 Impact factor: 5.191
Authors: Athe M N Tsibris; Zixin Hu; Roger Paredes; Kay E Leopold; Opass Putcharoen; Allison L Schure; Natalie Mazur; Eoin Coakley; Zhaohui Su; Roy M Gulick; Daniel R Kuritzkes Journal: J Virol Date: 2012-04-04 Impact factor: 5.103
Authors: Naveen K Vaidya; Libin Rong; Vincent C Marconi; Daniel R Kuritzkes; Steven G Deeks; Alan S Perelson Journal: PLoS Comput Biol Date: 2010-11-24 Impact factor: 4.475
Authors: N Wagner; C A Wyler-Lazarevic; S Yerly; C Samer; G Peytavin; K M Posfay-Barbe; A Calmy; J Ambrosioni Journal: New Microbes New Infect Date: 2015-02-27